Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
Cancer Drug Resistance · 2023 · 6 (2) · 327-331
DOI: 10.20517/cdr.2022.142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Drug Resistance, 2023. Verfasst von Liia Akhuba und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Health Sciences, Western Sydney University, Sydney, NSW 2145, Australia. Die Arbeit wurde bisher 13-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
In 2030, pancreatic ductal adenocarcinoma (PDAC) will become the second leading cause of cancer-related mortality in the world. Unfortunately, neither conventional chemotherapy nor novel immunotherapeutic strategies can provide durable responses and the survival prognosis remains very low. PDAC is notorious for its immune-resistant features and unique genomic landscape facilitating tumor escape from immunosurveillance. Novel immune-checkpoint inhibitors (ICI) failed to show promising efficacy and other multi-modal approaches are currently being validated in multiple clinical trials. In this paper, we provide our opinion on the major mechanisms responsible for PDAC resistance to ICI therapy and provide our view on future strategies which may overcome those barriers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Health Sciences, Western Sydney University, Sydney, NSW 2145, Australia.
- Accreditation Centre, RUDN University, Moscow 117198, Russia.
- Blacktown Clinical School, Western Sydney University, Sydney, NSW 2145, Australia.
- Blacktown Mt Druitt Hospital, Sydney, NSW 2145, Australia.
- Westmead Institute for Medical Research, Sydney, NSW 2145, Australia.
Zitieren
APA
Akhuba, L., Tigai, Z., & Shek, D. (2023). Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma. Cancer Drug Resistance, 6(2), 327-331. https://doi.org/10.20517/cdr.2022.142
Vancouver
Akhuba L, Tigai Z, Shek D. Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma. Cancer Drug Resistance. 2023;6(2):327-331. doi:10.20517/cdr.2022.142
BibTeX
@article{Akhuba2023,
author = {Akhuba, Liia and Tigai, Zhanna and Shek, Dmitrii},
title = {Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma},
journal = {Cancer Drug Resistance},
year = {2023},
volume = {6},
number = {2},
pages = {327--331},
doi = {10.20517/cdr.2022.142}
}
EUVIMED